Natural Ceramide Reverses Fas Resistance of Acid Sphingomyelinaseminus /minus Hepatocytes*

François ParisDagger , Heike Grassmé§, Aida CremestiDagger , Jonathan Zager, Yuman Fong, Adriana Haimovitz-Friedman||, Zvi Fuks||, Erich Gulbins§, and Richard KolesnickDagger **

From the Dagger  Laboratory of Signal Transduction, the Departments of || Radiation Oncology and  Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 and the § Department of Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105

Received for publication, September 25, 2000, and in revised form, November 15, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The role of the second messenger ceramide in Fas-mediated death requires clarification. To address this issue, we generated hepatocytes from paired acid sphingomyelinase (ASMase; asmase)+/+ and asmase-/- mice. asmase-/- hepatocytes, derived from 8-week-old mice, manifested normal sphingomyelin content and normal morphological, biochemical, and biologic features. Nonetheless, ASMase-deficient hepatocytes did not display rapid ceramide elevation or apoptosis in response to Jo2 anti-Fas antibody. asmase-/- hepatocytes were not inherently resistant to apoptosis because staurosporine, which did not induce early ceramide elevation, stimulated a normal apoptotic response. The addition of low nanomolar quantities of natural C16-ceramide, which by itself did not induce apoptosis, completely restored the apoptotic response to anti-Fas in asmase-/- hepatocytes. Other sphingolipids did not replace natural ceramide and restore Fas sensitivity. Overcoming resistance to Fas in asmase-/- hepatocytes by natural ceramide is evidence that it is the lack of ceramide and not ASMase which determines the apoptotic phenotype. The ability of natural ceramide to rescue the phenotype without reversing the genotype provides evidence that ceramide is obligate for Fas induction of apoptosis in hepatocytes.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Engagement of Fas/CD95/APO-1 receptors by Fas ligand or anti-Fas antibody results in formation of a death-inducing signaling complex comprised of the adaptor molecules FADD/MORT-1 and caspase 8, resulting in release of active caspase 8 to initiate the apoptotic process (1). Apoptosis, however, proceeds only after an ensuing commitment step, which allows effector caspase activation. Recently, Peter and co-workers (2) provided evidence that the quality and quantity of the activated caspase 8 signal are regulated in a cell type-specific fashion and suggested that Fas initiates apoptosis via two different mechanisms. In type I cells, apoptosis occurs after high caspase 8 activation, which signals exclusively via a hierarchical caspase cascade, independent of mitochondrial dysfunction. In contrast, apoptosis in type II cells proceeds after minimal caspase 8 activation through an amplification cascade involving mitochondrial dysfunction, release of mitochondrial cytochrome c, and activation of Apaf-1 and caspase 9. Although many of the upstream elements in type II apoptosis are unknown, this event is inhibited by Bcl-2 and can be mimicked by exogenous addition of short chain ceramides. In both mechanisms, apoptosis eventually ensues after effector caspases, such as 3 and 7, are activated.

There are numerous reports of early ceramide elevation upon Fas activation (3, 4). Ceramide is a second messenger in an evolutionarily conserved stress response pathway that, in different cells, signals events as diverse as differentiation, proliferation, and apoptosis (3). Ceramide is generated from sphingomyelin by the action of a neutral or acid sphingomyelinase (NSMase1 or ASMase) or by de novo synthesis coordinated through the enzyme ceramide synthase (5). In response to Fas ligation, ceramide elevation is often biphasic, a rapid elevation with return to baseline is followed by a more prolonged elevation that is progressive. Evidence has been provided that both ASMase and NSMase might contribute to Fas-mediated ceramide elevation (6, 7), with ASMase involvement in the acute event. Recent investigations titrated down the amount of FADD or procaspase 8 transfected into HeLa and 293T cells to the point where they no longer induced apoptosis (8). Under these conditions, FADD and procaspase 8 nonetheless induced maximal ceramide generation, which was inhibitable by the initiator caspase inhibitor CrmA. These experiments provided evidence that ceramide generation is initiator caspase-dependent and occurs prior to commitment to the effector phase of the apoptotic process.

Whether the ceramide generated in response to Fas ligation is involved in the apoptotic process or is an epiphenomenon is a matter of ongoing debate. Testi and co-workers (9) claimed that Epstein-Barr virus-transformed lymphoblasts from Niemann-Pick disease (NPD) patients, which have an inherited deficiency of ASMase activity, displayed deficits in ceramide generation and apoptosis, whereas Borst and co-workers (10) found no differences. Recently, Green and co-workers (7) reported partial resistance to Jo2 anti-Fas-induced liver failure and death in asmase-/- mice in vivo. Furthermore, the establishment of primary cultures of several cell types derived from asmase-/- mice showed that hepatocytes (11) but not thymocytes (7) displayed resistance to Fas-mediated death. Although these genetic models tended to support a possible cell type-specific role for ASMase, and indirectly for ceramide, in Fas-induced apoptosis, other interpretations are possible. For instance, the NPD lymphoblasts described above were transformed with Epstein-Barr virus and the transformation process itself, as well as known Epstein-Barr virus strain-specific phenotypic differences (12-14), might have affected the outcome. Further, it remains possible that the resistance of cells from asmase-/- mice to Fas-induced apoptotic death might result from subtle alterations in membrane structure/function independent of ceramide itself.

To address directly the issue of the involvement of ceramide in Fas-mediated death, we examined the ability of primary cultures of hepatocytes derived from asmase+/+ and asmase-/- mice to undergo apoptosis in response to anti-Fas antibody. Like embryonic fibroblasts and thymocytes from asmase-/- mice (15), asmase-/- hepatocytes displayed normal sphingomyelin content and were indistinguishable from asmase+/+ hepatocytes by numerous morphological, biochemical, and biologic criteria. In contrast to wild type hepatocytes, however, ASMase-deficient hepatocytes failed to generate ceramide upon activation of Fas and were markedly resistant to Fas-mediated apoptotic death. Further, the addition of low nanomolar quantities of natural C16-ceramide, which by itself does not effect apoptosis, restored Fas-mediated apoptosis in asmase-/- hepatocytes. Overcoming apoptosis resistance by provision of natural ceramide is evidence that it is the lack of ceramide and not ASMase that determines the Fas sensitivity. The ability of natural ceramide to rescue the phenotype without reversing the genotype provides evidence that ceramide is obligate for efficient Fas induction of apoptosis in hepatocytes.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Animals-- ASMase knockout mice, maintained in a sv129 × C57BL/6 background, are propagated using heterozygous breeding pairs and genotyped as described (16). Experimental mice were 8-12 weeks old and sacrificed by carbon dioxide asphyxiation.

Ex Vivo Hepatocyte Culture Prepared by Mechanical Disruption-- Harvested livers were washed three times with phosphate-buffered saline at 37 °C, cut into small pieces, and separated into small clumps with a spatula. Individual hepatocytes were dispersed mechanically by passage through an 18-gauge needle, filtered through a 100-µM cell strainer, washed once with RPMI 1640 complete medium, and resuspended into the same medium containing 10% fetal bovine serum, as described (11). Viability was always greater than 95% as defined by trypan blue exclusion analysis. After 1 h, cells (5 × 106/ml) were placed in 24-well plates pretreated with 10 mg/ml bovine serum albumin fraction V (Sigma) in an incubator at 37 °C with 5% CO2 atmosphere. Cells were treated with anti-Fas Jo2 antibody (Pharmingen) or staurosporine (Sigma) for the indicated times while under constant agitation using a nutator (Becton Dickinson).

Ex Vivo Hepatocyte Culture Prepared by Collagenase Perfusion-- Hepatocytes were isolated by cannulation of the portal vein and retrograde in situ collagenase perfusion according the method described previously by Picardo et al. (17). Briefly, livers were perfused under sterile conditions at 40 °C consecutively with Leffert's buffer (100 mM HEPES, pH 7.4, 30 mM KCl, 1.3 M NaCl, 10 mM NaH2PO4, 100 mM D-glucose) with 0.5 mM EGTA for 4 min, without EGTA for 2 min, and then with 33% (w/v) collagenase type V (Roche) and 5 mM CaCl2 for 12 min using an Easy Load perfusion pump (Masterflex, Cole Parmer; flow rate of 16 ml/min). The liver was then minced in cold Leffert's buffer containing 5 mM CaCl2, and isolated hepatocytes were filtered through a 100-µm cell strainer. Isolated hepatocytes were washed twice at 50 × g and resuspended into RPMI 1640 complete medium containing 10% fetal bovine serum. Viability was always greater than 95% using this method.

Sphingolipid Treatment-- Cells (5 × 106/ml) were pretreated for 10 min with C16-ceramide, sphingosine, sphingomyelin, sphinganine, sphingosine 1-phosphate (Biomol), or C16-dihydroceramide (Toronto Research Chemicals, Inc.) in dodecane:ethanol (2:98, v/v; 0.05% final concentration) or diluent alone prior to the addition of Jo2 antibody.

Fluorescence-activated Cell Sorting (FACS)-- A single cell suspension of hepatocytes was washed twice and resuspended into 100 µl of H/S (132 mM NaCl, 20 mM HEPES, 5 mM KCl, 1 mM CaCl2, 0.7 mM MgCl2, 0.8 mM MgSO4) containing 2% fetal calf serum and 0.2% NaN3 supplemented with 1 µg/ml anti-Fas Jo2 antibody or an isotype-specific control immunoglobulin. After 45 min on ice, cells were washed with the same buffer and stained with a fluorescein isothiocyanate-coupled anti-hamster antibody (Pharmingen 12084D). Cell surface Fas was determined in labeled cells by flow cytometry, as described (11).

Diacylglycerol Kinase Assay-- Hepatocytes, stimulated for the indicated times with Jo2, were lysed in 25 mM HEPES, pH 7.4, 0.5% SDS, 1% Triton X-100, 10 mM EDTA, 10 mM each sodium pyrophosphate and sodium fluoride, 10 µg/ml each aprotinin and leupeptin, 125 mM NaCl. Lipids were extracted, and ceramide was quantified by the diacylglycerol kinase reaction as described previously (18).

Terminal Nucleotidyl Transferase Assay-- Hepatocytes were trypsinized after treatment with anti-Fas antibody or staurosporine and then permeabilized with a solution of 0.1% Triton X-100 and 0.1% sodium citrate at 4 °C for 5 min. Apoptosis was assessed by terminal nucleotidyl transferase according to the manufacturer's instructions (Roche, Indianapolis, IN). At least 200 cells were counted for each point.

Ethidium Bromide/Acridine Orange Staining-- Cells were stained with 4 µg/ml each ethidium bromide and acridine orange for 10 min and analyzed by fluorescence microscopy as described (19).

DEVDase Assay-- The fluorogenic substrate Ac-DEVD-AFC was used to measure caspase 3-like activity according to the manufacturer's instructions (Kamiya, Seattle, WA).

Statistical Analysis-- Statistical analysis was performed by Student's t test and t test for correlation coefficient.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Characterization of asmase-/- Hepatocytes-- We reported recently that 8-10 week old asmase-/- mice derived from our colony display normal sphingomyelin content in multiple tissues (15, 20). Consequently, these animals are physiologically normal and do not manifest NPD, as NPD requires sphingomyelin accumulation (21). In the present studies, we generated primary cultures of hepatocytes from livers of asmase+/+ and asmase-/- mice. Livers from 8-week-old ASMase-deficient mice displayed normal architecture, and isolated hepatocytes manifested physiologic morphology. No measurable ASMase activity was detected in the asmase-/- hepatocytes (Table I); NSMase activity was unchanged. Further, asmase-/- hepatocytes manifested normal sphingomyelin and ceramide content (Table I), consistent with the observation that these animals develop normally into adulthood (15, 22, 23). The distribution of glycosphingolipid-enriched microdomains, a compartment putatively involved in ceramide signaling (24) and their content was similar in asmase+/+ and asmase-/- hepatocytes (Table I), as was the expression of Fas on the cell surface, measured by FACS using the Jo2 anti-Fas antibody (Fig. 1). Similarly, the levels of factors known to participate in Fas-mediated apoptosis in hepatocytes including FADD/MORT-1, Bid, Bcl-2, Apaf-1, and caspases 3, 8, and 9 were identical in asmase+/+ and asmase-/- hepatocytes (Table I). Moreover, the activation patterns of p38, c-Jun terminal, and extracellular signal-regulated kinases in response epidermal growth factor, tumor necrosis factor-alpha , heat shock, and hyperosmolarity were also similar in asmase+/+ and asmase-/- hepatocytes (Table I). Thus, asmase+/+ and asmase-/- hepatocytes appeared similar as assessed by numerous criteria.


                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of asmase+/+ and asmase-/- hepatocytes
The "+" symbol is used to indicate optimal detection of an event.



View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   asmase+/+ and asmase-/- hepatocytes express comparable levels of cell surface Fas. The level of Fas on the surface of hepatocytes was determined by flow cytometry as described (11). To detect Fas, asmase+/+ and asmase-/- hepatocytes were stained with Jo2 and a fluorescein isothiocyanate-coupled anti-hamster secondary antibody (green and blue lines, respectively). For controls, asmase+/+ and asmase-/- hepatocytes were stained with an isotype-specific control antibody followed by fluorescein isothiocyanate-coupled secondary antibody (orange and red lines, respectively).

asmase-/- Hepatocytes Are Defective in Fas-induced Ceramide Generation-- To investigate whether ASMase-deficient cells displayed defects in Fas-mediated signaling through the sphingomyelin pathway, we treated primary cultures of asmase+/+ and asmase-/- hepatocytes with increasing concentrations of Jo2 anti-Fas antibody. Hepatocytes were treated in suspension, as Kass and co-workers (25) showed that plating hepatocytes as monolayers conferred Fas resistance, i.e. the development of a requirement for cycloheximide for death induction (25). In contrast, hepatocytes in suspension retained sensitivity to Fas-mediated death. Fig. 2A shows that asmase+/+ hepatocytes displayed dose-dependent elevation in ceramide content when measured at 5 min of treatment. As little as 50 ng/ml Jo2 increased ceramide content from a baseline of 170 ± 20 pmol/106 cells to 210 ± 20 pmol/106 cells, and a maximal increase to 515 ± 15 pmol/106 cells (p < 0.01) was achieved with 1,000 ng/ml. In contrast, asmase-/- hepatocytes failed to manifest increased ceramide levels at any Jo2 dose up to 8,000 ng/ml.



View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   asmase-/- hepatocytes are deficient in ceramide generation after Jo2 treatment. Panel A, ceramide levels in asmase+/+ and asmase-/- hepatocytes were determined by diacylglycerol kinase assay after treatment with the indicated concentrations of Jo2 monoclonal antibody. The data (mean ± S.D.) are compiled from two studies performed in duplicate. Panel B, time course of ceramide generation in asmase+/+ and asmase-/- hepatocytes after 500 ng/ml Jo2 monoclonal antibody determined as in panel A. The data (mean ± S.D.) are compiled from two studies performed in duplicate.

Studies were also performed to determine the time course of ceramide elevation after Jo2 treatment using a 500-ng/ml dose (Fig. 2B). In asmase+/+ hepatocytes, ceramide levels increased to 1.6-fold of control by 30 s (p < 0.01), peaked at 5 min, and remained elevated for at least 20 min. asmase-/- hepatocytes, however, did not demonstrate elevation of ceramide levels at any time up to 20 min. Thus, asmase-/- hepatocytes display a complete defect in the early phase of ceramide generation upon Jo2 treatment.

asmase-/- Hepatocytes Are Resistant to Anti-Fas-mediated Apoptosis-- To evaluate whether asmase-/- hepatocytes also displayed defects in Fas-mediated apoptosis, hepatocytes were rested for 1 h in RPMI 1640 complete medium containing 10% fetal bovine serum prior to treatment with Jo2 anti-Fas antibody. Prior investigations showed that Jo2 antibody induced time- and dose-dependent apoptosis in wild type hepatocytes in vivo and ex vivo (7, 11, 26-30). Initial studies determined the time course of induction of apoptosis in asmase+/+ hepatocytes as measured by terminal nucleotidyl transferase using 1,000 ng/ml Jo2 antibody, a maximally effective dose. Apoptosis was detected by 2 h and was maximal by 8 h (not shown). Subsequent investigations measured the dose dependence of Jo2-induced apoptosis in asmase+/+ hepatocytes after 8 h of treatment. As shown in Fig. 3A, apoptosis occurred over 2-3 logs of Jo2 doses; as little as 100 ng/ml Jo2 was effective; a maximal apoptotic effect was achieved using 2,000 ng/ml. Thus, the dose dependence for Jo2-induced ceramide generation is slightly lower than that for apoptosis. asmase-/- hepatocytes, which contain normal numbers of cell surface Fas receptors (Fig. 1), were nonetheless resistant to treatment with anti-Fas antibody. In contrast to the total resistance to ceramide generation, apoptosis was inducible by increasing the dose of Jo2 antibody about 1 log. Thus, apoptosis was elicited with a 2,000-ng/ml dose of Jo2 in asmase-/- hepatocytes and increased to a maximum at 8,000 ng/ml Jo2. Similar results were obtained using ethidium bromide and acridine orange staining to detect morphological changes of apoptosis (Fig. 3B). These studies indicate that asmase-/- hepatocytes can undergo ASMase-dependent and -independent apoptosis after Jo2 treatment.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 3.   asmase-/- hepatocytes are relatively resistant to anti-Fas Jo2 antibody. Panel A, hepatocytes were isolated from asmase+/+ and asmase-/- littermates, placed in 24-well plates precoated with bovine serum albumin, and treated with the indicated concentrations of anti-Fas monoclonal antibody. Cells were harvested after 8 h, and apoptosis assessed by terminal nucleotidyl transferase assay. 200 cells were evaluated per point. The data (mean ± S.E.) are compiled from three studies performed in duplicate. Panel B, apoptosis was also assessed in hepatocytes from asmase+/+ and asmase-/- littermates 8 h after the indicated doses of Jo2 by ethidium bromide/acridine orange staining as described (19). The data (mean ± S.E.) are compiled from six studies performed in triplicate.

Because the hepatocytes used in these studies were obtained by mechanical dispersion, we compared the effect of Jo2 to induce death using asmase+/+ and asmase-/- hepatocytes obtained by an alternative technique, in vivo collagenase treatment. For these studies, collagenase was delivered to intact livers after cannulation of the inferior hepatic vein and isolated hepatocytes derived as described (17). Using this approach, we again observed a 1-log deficit in apoptotic death in asmase-/- hepatocytes in suspension culture (not shown). Thus, by two separate techniques for hepatocyte isolation asmase-/- hepatocytes are defective in Fas-mediated apoptotic death. Unless otherwise indicated, subsequent studies used mechanical dispersion for hepatocyte isolation.

The apoptotic response was also assessed using a biochemical assay for caspase 3 activity after a dose of 1,000 ng/ml Jo2 (see Fig. 5B). Consistent with the results shown in Fig. 3A and 3B, asmase+/+ hepatocytes showed a 4.1 ± 0.1-fold increase in caspase activity at 8 h of Jo2 treatment while asmase-/- hepatocytes did not exhibit any increase in caspase 3 activity. Hence, multiple assays confirm that lack of ASMase renders cells resistant to Jo2-induced apoptosis.

asmase-/- Hepatocytes Are Sensitive to Staurosporine-induced Apoptosis-- To evaluate whether the mutation leading to the asmase-/- phenotype resulted in a general inactivation of the apoptotic machinery, hepatocytes were exposed to a different proapoptotic stimulus. Staurosporine is a potent protein kinase inhibitor capable of inducing apoptosis by a mechanism that does not involve ASMase-mediated ceramide generation (20). As in other cell types, staurosporine failed to generate ceramide within the first 30 min in either asmase+/+ or asmase-/- hepatocytes (not shown). Nonetheless, staurosporine induced apoptosis in asmase+/+ hepatocytes within 6-8 h (Fig. 4), which peaked by 12 h (not shown). A dose as low as 0.1 µM staurosporine induced apoptosis in 30% of the population at 12 h, whereas 75% apoptosis was observed with 5-10 µM staurosporine (Fig. 4). In contrast to the Fas experiments, the asmase-/- hepatocytes showed no resistance to staurosporine-induced cell death, and the level of apoptosis was essentially identical to that of the asmase+/+ hepatocytes (Fig. 4). These studies indicate that asmase-/- hepatocytes are fully competent in generating an apoptotic response and suggest that the lack of apoptosis to anti-Fas may be specifically associated with ASMase deficiency.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Staurosporine induces apoptosis in asmase-/- hepatocytes. The dose-response of staurosporine-induced apoptosis after 12 h was measured by terminal nucleotidyl transferase assay as in Fig. 3A. The data (mean ± S.D.) are compiled from two studies performed in duplicate.

Natural Ceramide Can Rescue the Apoptotic Response of asmase-/- Hepatocytes to Anti-Fas-- To provide definitive evidence that the lack of ceramide is the cause of the resistance of asmase-/- cells to anti-Fas treatment, we pretreated asmase-/- hepatocytes with low doses of natural C16-ceramide for 10 min prior to the treatment with 1,000 ng/ml Jo2. This dose was selected because it provides the greatest discrimination in apoptotic responses between asmase+/+ and asmase-/- hepatocytes. Fig. 5A shows that 5-25 nM C16-ceramide was without direct effect on apoptosis, nor did it alter the apoptotic response to 1,000 ng/ml Jo2 in asmase+/+ hepatocytes. However, 5-25 nM C16-ceramide restored the sensitivity of asmase-/- hepatocytes to Jo2 antibody. In fact, at 25 nM C16-ceramide the apoptotic response of asmase-/- hepatocytes was indistinguishable from that of asmase+/+ hepatocytes. Identical results were obtained using hepatocytes isolated by collagenase digestion (not shown). The capacity of natural ceramide to rescue the ASMase-deficient apoptotic phenotype was also evaluated using the caspase 3 biochemical assay. As shown in Fig. 5B, natural ceramide alone at 25 nM also conferred Jo2-induced caspase activation onto asmase-/- hepatocytes. Thus, the addition of natural ceramide to the asmase-/- hepatocytes rescues the apoptotic phenotype without reverting the genotype, providing proof that the resistance of ASMase-deficient hepatocytes to anti-Fas antibody is mediated by the lack of ceramide generation and not by the lack of ASMase.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   Natural C16-ceramide but not other sphingolipids restores the sensitivity of asmase-/- hepatocytes to anti-Fas Jo2 antibody. Panel A, hepatocytes were handled as in Fig. 3A and for some incubations pretreated for 10 min with the indicated concentration of C16-ceramide in dodecane:ethanol (2:98, v/v; 0.05% final concentration) or diluent alone prior to the addition of 1,000 ng/ml Jo2 antibody. The data (mean ± S.E.) are compiled from three studies performed in duplicate. Panel B, caspase 3-like activity measured by cleavage of the fluorogenic substrate Ac-DEVD-AFC. Hepatocytes were handled as in Fig. 3A, then cell lysates were prepared in RIPA buffer, and DEVDase activity was measured as described under "Materials and Methods." The data (mean ± S.D.) are compiled from two studies performed in duplicate. Panel C, hepatocytes were handled as in Fig. 4A except some incubations received 50 nM C16-dihydroceramide (C16 dh ceramide), sphingomyelin, sphingosine, sphinganine, or sphingosine 1-phosphate (S 1-P), as indicated. The data (mean ± S.E.) are compiled from five studies performed in duplicate.

Natural C16-ceramide but Not Other Sphingolipids Rescues ASMase-deficient Hepatocytes-- To address further the specific role of ceramide in Fas-mediated apoptosis, we investigated the capacity of other sphingolipids to restore Jo2-mediated death to asmase-/- hepatocytes. Fig. 5C shows that although 25 nM C16-ceramide rescued the apoptotic phenotype of asmase-/- hepatocytes, as much as a 50 nM concentration of other sphingolipids including C16-dihydroceramide, sphingomyelin, sphingosine 1-phosphate, sphingosine, or sphinganine failed to rescue Jo2-induced apoptosis. It should be noted that these other sphingolipids also did not induce apoptosis in untreated asmase+/+ or asmase-/- hepatocytes (not shown). Thus, natural ceramide specifically restores Jo2-induced apoptosis to asmase-/- hepatocytes.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The present studies show that primary cultures of hepatocytes from asmase-/- mice display a large deficit in anti-Fas induced death ex vivo compared with hepatocytes from asmase+/+ littermates. In contrast to asmase+/+ hepatocytes, asmase-/- hepatocytes failed to demonstrate an early ceramide elevation despite containing normal levels of sphingomyelin. Further, the apoptosis resistance of asmase-/- hepatocytes was overcome by natural ceramide. This provides proof that it is the lack of ceramide, and not ASMase, which determines the asmase-/- phenotype. Consistent with this notion, only natural ceramide and not other sphingolipids could restore Fas sensitivity. Apoptosis resistance could also be overcome by very high doses of Jo2 anti-Fas. The mechanism for this ceramide-independent apoptosis induction by Jo2 may involve superaggregation of trimerized Fas (31-33). However, it is not certain that this ceramide-independent apoptotic mechanism is operative under physiologic conditions. In this regard, two independent in vivo events, phytohemagglutinin-induced hepatitis, and anti-CD4-induced deletion of CD3+ and CD4+ cells, which are mediated by Fas ligand up-regulation on peripheral blood lymphocytes, are completely defective in our asmase-/- mice despite normal Fas ligand up-regulation (11).

Prior studies reported that ASMase-deficient mice were partially resistant to animal death upon intravenous injection of Jo2. In contrast to the 1-log defect in apoptosis observed in hepatocytes ex vivo, ASMase-deficient mice displayed only a moderate reduction in sensitivity to the lethal effect of Jo2. The reason for the difference in requirement for ASMase for these events is presently uncertain. However, animals expressing a Bcl-2 transgene only in their livers were defective in Fas-induced hepatitis yet displayed little resistance to death (34). Thus, it is not clear that rapid hepatic failure is causative in animal death after anti-Fas. Because the dose dependence for hepatocyte death in vivo has not been determined in animals treated with anti-Fas, a comparison of the effects of Jo2 in vivo and in vitro is not presently possible.

The present studies add to emerging data indicating that young ASMase-deficient animals display normal sphingomyelin levels and hence do not manifest evidence of NPD (35). NPD is caused by the progressive accumulation of sphingomyelin (35). It is therefore not surprising that hepatocytes, murine embryonic fibroblasts, and thymocytes from 8-10-week-old asmase-/- mice appear normal as assessed by a battery of biochemical, histological, and biological tests (7, 15, 20, 22, 23). Consistent with this observation, the asmase-/- mice develop normally into adulthood. In our colony, the earliest clinical manifestation of NPD, a resting tremor, begins at 12-16 weeks of age. Routinely, our asmase-/- mice survive to 9.6 ± 0.4 (mean ± S.D.) months of age. Nevertheless, asmase-/- mice and primary cultures of cells from young asmase-/- mice display specific defects in apoptosis. asmase-/- hepatocytes display resistance to Fas-induced death ex vivo and, as mentioned above, to phytohemagglutinin-induced hepatitis in vivo (11). Similarly, murine embryonic fibroblasts from asmase-/- mice display complete resistance to ionizing radiation-induced apoptosis and partial resistance to tumor necrosis factor-alpha /actinomycin D- and serum withdrawal-induced apoptosis (20). In both hepatocytes and murine embryonic fibroblasts, however, sensitivity to staurosporine is maintained, indicating that the use of the sphingomyelin pathway within any cell may be stress type-specific. asmase-/- mice also display defects in apoptosis in vivo. Endothelium in the lung and throughout the central nervous system of these mice is almost completely resistant to induction of apoptosis with doses as high as 100 Gray, whereas asmase+/+ littermates display dose-dependent apoptosis beginning with as little as 5 Gray (22, 23). ASMase-deficient mice also manifest a marked defect in the ovarian developmental program (36). A failure to delete oocytes normally in asmase mutant females during embryogenesis results in ovarian hyperplasia at birth (37). Further, oocytes isolated from adult ASMase-deficient females are markedly resistant to doxorubicin-induced apoptotic death (36). In contrast, thymic cells from asmase-/- mice display no resistance to apoptosis in vivo or ex vivo by any stimulus tested so far (7, 23). These data show the use of the sphingomyelin pathway for induction of apoptosis is stress type- and cell type-specific.

The present studies extend the literature documenting rapid sphingolipid metabolism in cells destined to undergo apoptosis. In our survey of the literature we found 50 publications of stimulated sphingomyelinase activation, sphingomyelin hydrolysis, and/or ceramide elevation within the first 5-15 min of exposure to proapoptotic stimuli, well prior to the effector stage of the apoptotic process. The distribution of these reports is as follows: 14 for Fas (6-9, 38-47), 6 for tumor necrosis factor-alpha (48-53), 8 for ionizing radiation (23, 54-60), 11 for chemical agents (61-71), and 11 for other stresses (72-82). Thus we cannot explain the inability of Borst and co-workers (83) to detect early sphingolipid changes after many of the same proapoptotic stimuli. However, we do not dispute that ceramide might be generated in some instances, as they have suggested, at a later stage, prior to or possibly even during the effector stage of apoptosis.

In summary, the present investigation provides evidence that ceramide is required for optimal Fas signaling of the death response in hepatocytes. Preliminary data suggest that ceramide is required for capping of Fas, an event necessary for transmembrane signal transmission for other cell surface receptors.2 Overcoming apoptosis resistance by natural ceramide is evidence that it is the lack of ceramide, and not ASMase, which determines the Fas-resistant phenotype in hepatocytes.


    ACKNOWLEDGEMENTS

We thank Desiree Ehleiter, Brian DeRubertis, and Niraj Gusani for technical assistance.


    FOOTNOTES

* This work was supported by National Institutes of Health Grants CA42385 (to R. K.), CA52462 (to Z. F.), CA72632 (to Y. F.), and CA61524 (to Y. F.) and by Deutsche Forschungsgemeinschaft Grant Gu 335/2-3 (to E. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021. Tel.: 212-639-7558; Fax: 212-639-2767; E-mail: r-kolesnick@ski.mskcc.org.

Published, JBC Papers in Press, November 28, 2000, DOI 10.1074/jbc.M008732200

2 E. Gulbins and R. Kolesnick, unpublished observation.


    ABBREVIATIONS

The abbreviations used are: NSMase, neutral sphingomyelinase; ASMase, acid sphingomyelinase; NPD, Niemann-Pick disease; FACS, fluorescence-activated cell sorting; AFC, 7- amino-4-trifluro-coumarin.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Walczak, H., and Krammer, P. H. (2000) Exp. Cell Res. 256, 58-66[CrossRef][Medline] [Order article via Infotrieve]
2. Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. M., Krammer, P. H., and Peter, M. E. (1998) EMBO J. 17, 1675-1687[Abstract/Free Full Text]
3. Hannun, Y. A. (1996) Science 274, 1855-1859[Abstract/Free Full Text]
4. Mathias, S., Pena, L. A., and Kolesnick, R. N. (1998) Biochem. J. 335, 465-480[Medline] [Order article via Infotrieve]
5. Kolesnick, R. N., and Kronke, M. (1998) Annu. Rev. Physiol. 60, 643-665[CrossRef][Medline] [Order article via Infotrieve]
6. Cifone, M. G., De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., and Testi, R. (1994) J. Exp. Med. 180, 1547-1552[Abstract]
7. Lin, T., Genestier, L., Pinkoski, M. J., Castro, A., Nicholas, S., Mogil, R., Paris, F., Fuks, Z., Schuchman, E. H., Kolesnick, R. N., and Green, D. R. (2000) J. Biol. Chem. 275, 8657-8663[Abstract/Free Full Text]
8. Grullich, C., Sullards, M. C., Fuks, Z., Merrill, A. H., Jr., and Kolesnick, R. (2000) J. Biol. Chem. 275, 8650-8656[Abstract/Free Full Text]
9. De Maria, R., Rippo, M. R., Schuchman, E. H., and Testi, R. (1998) J. Exp. Med 187, 897-902[Abstract/Free Full Text]
10. Cock, J. G., Tepper, A. D., de Vries, E., van Blitterswijk, W. J., and Borst, J. (1998) J. Biol. Chem. 273, 7560-7565[Abstract/Free Full Text]
11. Kirschnek, S., Paris, F., Weller, M., Grassme, H., Ferlinz, K., Riehle, A., Fuks, Z., Kolesnick, R., and Gulbins, E. (2000) J. Biol. Chem. 275, 27316-27323[Abstract/Free Full Text]
12. Miller, C. L., Lee, J. H., Kieff, E., and Longnecker, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 772-776[Abstract]
13. Miller, C. L., Burkhardt, A. L., Lee, J. H., Stealey, B., Longnecker, R., Bolen, J. B., and Kieff, E. (1995) Immunity 2, 155-166[Medline] [Order article via Infotrieve]
14. Khanna, K. K., Yan, J., Watters, D., Hobson, K., Beamish, H., Spring, K., Shiloh, Y., Gatti, R. A., and Lavin, M. F. (1997) J. Biol. Chem. 272, 9489-9495[Abstract/Free Full Text]
15. Lozano, J., Morales, A., Cremesti, A., Fuks, Z., Tilly, J. L., Schuchman, E., Gulbins, E., and Kolesnick, R. (2001) Cell Death Differ. 8, 100-102[CrossRef][Medline] [Order article via Infotrieve].
16. Horinouchi, K., Erlich, S., Perl, D. P., Ferlinz, K., Bisgaier, C. L., Sandhoff, K., Desnick, R. J., Stewart, C. L., and Schuchman, E. H. (1995) Nat. Genet. 10, 288-293[Medline] [Order article via Infotrieve]
17. Picardo, A., Fong, Y., Karpoff, H. M., Yeh, S., Blumgart, L. H., and Brennan, M. F. (1996) J. Surg. Res. 63, 452-456[CrossRef][Medline] [Order article via Infotrieve]
18. Bose, R., Chen, P., Loconti, A., Grullich, C., Abrams, J. M., and Kolesnick, R. N. (1998) J. Biol. Chem. 273, 28852-28859[Abstract/Free Full Text]
19. Coligan, J. E., Dunn, B. M., Ploegh, H. L., Speicher, D. W., and Wingfield, P. T. (1991) Current Protocols in Immunology , pp. 3.17.2-3.17.4, Wiley-Interscience, New York
20. Lozano, J., Menendez, S., Morales, A., Ehleiter, D., Liao, W.-C., Wagman, R., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. (2001) J. Biol. Chem. 276, 442-448[Abstract/Free Full Text]
21. Brady, R. O. (1998) Arch. Neurol. 55, 1055-1056[Abstract/Free Full Text]
22. Pena, L. A., Fuks, Z., and Kolesnick, R. N. (2000) Cancer Res. 60, 321-327[Abstract/Free Full Text]
23. Santana, P., Pena, L. A., Haimovitz-Friedman, A., Martin, S., Green, D., McLoughlin, M., Cordon-Cardo, C., Schuchman, E. H., Fuks, Z., and Kolesnick, R. (1996) Cell 86, 189-199[Medline] [Order article via Infotrieve]
24. Okamoto, T., Schlegel, A., Scherer, P. E., and Lisanti, M. P. (1998) J. Biol. Chem. 273, 5419-5422[Free Full Text]
25. Jones, R. A., Johnson, V. L., Buck, N. R., Dobrota, M., Hinton, R. H., Chow, S. C., and Kass, G. E. (1998) Hepatology 27, 1632-1642[Medline] [Order article via Infotrieve]
26. de la Coste, A., Fabre, M., McDonell, N., Porteu, A., Gilgenkrantz, H., Perret, C., Kahn, A., and Mignon, A. (1999) Am. J. Physiol. 277, G702-G708[Abstract/Free Full Text]
27. Woo, M., Hakem, A., Elia, A. J., Hakem, R., Duncan, G. S., Patterson, B. J., and Mak, T. W. (1999) J. Immunol. 163, 4909-4916[Abstract/Free Full Text]
28. Yamamoto, M., Miura, N., Ohtake, N., Amagaya, S., Ishige, A., Sasaki, H., Komatsu, Y., Fukuda, K., Ito, T., and Terasawa, K. (2000) Gastroenterology 118, 380-389[Medline] [Order article via Infotrieve]
29. Yin, X. M., Wang, K., Gross, A., Zhao, Y., Zinkel, S., Klocke, B., Roth, K. A., and Korsmeyer, S. J. (1999) Nature 400, 886-891[CrossRef][Medline] [Order article via Infotrieve]
30. Takehara, T., Hayashi, N., Tatsumi, T., Kanto, T., Mita, E., Sasaki, Y., Kasahara, A., and Hori, M. (1999) Gastroenterology 117, 661-668[Medline] [Order article via Infotrieve]
31. Huang, D. C., Hahne, M., Schroeter, M., Frei, K., Fontana, A., Villunger, A., Newton, K., Tschopp, J., and Strasser, A. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14871-14876[Abstract/Free Full Text]
32. Golstein, P. (2000) Science 288, 2328-2329[Free Full Text]
33. Siegel, R. M., Frederiksen, J. K., Zacharias, D. A., Chan, F. K., Johnson, M., Lynch, D., Tsien, R. Y., and Lenardo, M. J. (2000) Science 288, 2354-2357[Abstract/Free Full Text]
34. Rodriguez, I., Matsuura, K., Khatib, K., Reed, J. C., Nagata, S., and Vassalli, P. (1996) J. Exp. Med. 183, 1031-1036[Abstract]
35. Schuchman, E. H., and Desnick, R. J. (1994) in The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R. , Beaudet, A. L. , Sly, W. S. , and Valle, D., eds) , pp. 2601-2624, McGraw-Hill, New York
36. Morita, Y., Perez, G. I., Paris, F., Miranda, S. R., Ehleiter, D., Xie, Z., Reed, J. C., Haimovitz-Friedman, A., Fuks, Z., Schuchman, E. H., Kolesnick, R. N., and Tilly, J. L. (2000) Nat. Med. 6, 1109-1114[CrossRef][Medline] [Order article via Infotrieve]
37. Morita, Y., and Tilly, J. L. (2000) Ann. N. Y. Acad. Sci. 905, 209-220[Abstract/Free Full Text]
38. Brenner, B., Ferlinz, K., Grassme, H., Weller, M., Koppenhoefer, U., Dichgans, J., Sandhoff, K., Lang, F., and Gulbins, E. (1998) Cell Death Differ. 5, 29-37[CrossRef][Medline] [Order article via Infotrieve]
39. Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., and Spiegel, S. (1996) Nature 381, 800-803[CrossRef][Medline] [Order article via Infotrieve]
40. De Maria, R., Boirivant, M., Cifone, M. G., Roncaioli, P., Hahne, M., Tschopp, J., Pallone, F., Santoni, A., and Testi, R. (1996) J. Clin. Invest. 97, 316-322[Abstract/Free Full Text]
41. De Maria, R., Rippo, M. R., Schuchman, E. H., and Testi, R. (1998) J. Exp. Med. 187, 897-902[Abstract/Free Full Text]
42. Genestier, L., Prigent, A. F., Paillot, R., Quemeneur, L., Durand, I., Banchereau, J., Revillard, J. P., and Bonnefoy-Berard, N. (1998) J. Biol. Chem. 273, 5060-5066[Abstract/Free Full Text]
43. Gulbins, E., Brenner, B., Schlottmann, K., Welsch, J., Heinle, H., Koppenhoefer, U., Linderkamp, O., Coggeshall, K. M., and Lang, F. (1996) Immunology 89, 205-212[Medline] [Order article via Infotrieve]
44. Redondo, C., Flores, I., Gonzalez, A., Nagata, S., Carrera, A. C., Merida, I., and Martinez, A. C. (1996) J. Clin. Invest. 98, 1245-1252[Abstract/Free Full Text]
45. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. (1996) Nature 380, 75-79[CrossRef][Medline] [Order article via Infotrieve]
46. Cuvillier, O., Edsall, L., and Spiegel, S. (2000) J. Biol. Chem. 275, 15691-15700[Abstract/Free Full Text]
47. Furuke, K., and Bloom, E. T. (1998) Int. Immunol. 10, 1261-1272[Abstract]
48. Burow, M. E., Weldon, C. B., Collins-Burow, B. M., Ramsey, N., McKee, A., Klippel, A., McLachlan, J. A., Clejan, S., and Beckman, B. S. (2000) J. Biol. Chem. 275, 9628-9635[Abstract/Free Full Text]
49. Cai, Z., Bettaieb, A., Mahdani, N. E., Legres, L. G., Stancou, R., Masliah, J., and Chouaib, S. (1997) J. Biol. Chem. 272, 6918-6926[Abstract/Free Full Text]
50. De Nadai, C., Sestili, P., Cantoni, O., Lievremont, J. P., Sciorati, C., Barsacchi, R., Moncada, S., Meldolesi, J., and Clementi, E. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 5480-5485[Abstract/Free Full Text]
51. Ishizuka, N., Yagui, K., Tokuyama, Y., Yamada, K., Suzuki, Y., Miyazaki, J., Hashimoto, N., Makino, H., Saito, Y., and Kanatsuka, A. (1999) Metabolism 48, 1485-1492[Medline] [Order article via Infotrieve]
52. Ohta, H., Yatomi, Y., Sweeney, E. A., Hakomori, S., and Igarashi, Y. (1994) FEBS Lett. 355, 267-270[CrossRef][Medline] [Order article via Infotrieve]
53. Schwandner, R., Wiegmann, K., Bernardo, K., Kreder, D., and Kronke, M. (1998) J. Biol. Chem. 273, 5916-5922[Abstract/Free Full Text]
54. Bruno, A. P., Laurent, G., Averbeck, D., Demur, C., Bonnet, J., Bettaieb, A., Levade, T., and Jaffrezou, J. P. (1998) Cell Death Differ. 5, 172-182[CrossRef][Medline] [Order article via Infotrieve]
55. Chmura, S. J., Nodzenski, E., Beckett, M. A., Kufe, D. W., Quintans, J., and Weichselbaum, R. R. (1997) Cancer Res. 57, 1270-1275[Abstract]
56. Chmura, S. J., Nodzenski, E., Kharbanda, S., Pandey, P., Quintans, J., Kufe, D. W., and Weichselbaum, R. R. (2000) Mol. Pharmacol. 57, 792-796[Abstract/Free Full Text]
57. Haimovitz-Friedman, A., Kan, C. C., Ehleiter, D., Persaud, R. S., McLoughlin, M., Fuks, Z., and Kolesnick, R. N. (1994) J. Exp. Med. 180, 525-535[Abstract]
58. Kelly, M. L., Tang, Y., Rosensweig, N., Clejan, S., and Beckman, B. S. (1998) Blood 92, 416-424[Abstract/Free Full Text]
59. Liao, W. C., Haimovitz-Friedman, A., Persaud, R. S., McLoughlin, M., Ehleiter, D., Zhang, N., Gatei, M., Lavin, M., Kolesnick, R., and Fuks, Z. (1999) J. Biol. Chem. 274, 17908-17917[Abstract/Free Full Text]
60. Zundel, W., and Giaccia, A. (1998) Genes Dev. 12, 1941-1946[Abstract/Free Full Text]
61. Allouche, M., Bettaieb, A., Vindis, C., Rousse, A., Grignon, C., and Laurent, G. (1997) Oncogene 14, 1837-1845[CrossRef][Medline] [Order article via Infotrieve]
62. Chiu, S. M., Davis, T. W., Meyers, M., Ahmad, N., Mukhtar, H., and Separovic, D. (2000) Int. J. Oncol. 16, 423-427[Medline] [Order article via Infotrieve]
63. Chmura, S. J., Mauceri, H. J., Advani, S., Heimann, R., Beckett, M. A., Nodzenski, E., Quintans, J., Kufe, D. W., and Weichselbaum, R. R. (1997) Cancer Res. 57, 4340-4347[Abstract]
64. Cifone, M. G., Migliorati, G., Parroni, R., Marchetti, C., Millimaggi, D., Santoni, A., and Riccardi, C. (1999) Blood 93, 2282-2296[Abstract/Free Full Text]
65. Come, M. G., Bettaieb, A., Skladanowski, A., Larsen, A. K., and Laurent, G. (1999) Int. J. Cancer 81, 580-587[CrossRef][Medline] [Order article via Infotrieve]
66. Galve-Roperh, I., Sanchez, C., Cortes, M. L., del Pulgar, T. G., Izquierdo, M., and Guzman, M. (2000) Nat. Med. 6, 313-319[CrossRef][Medline] [Order article via Infotrieve]
67. Jaffrezou, J. P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre, N., Vermeersch, S., Rousse, A., and Laurent, G. (1996) EMBO J. 15, 2417-2424[Abstract]
68. Mansat-de Mas, V., Bezombes, C., Quillet-Mary, A., Bettaieb, A., D'Orgeix, A, D., Laurent, G., and Jaffrezou, J. P. (1999) Mol. Pharmacol. 56, 867-874[Abstract/Free Full Text]
69. Mansat, V., Bettaieb, A., Levade, T., Laurent, G., and Jaffrezou, J. P. (1997) FASEB J. 11, 695-702[Abstract/Free Full Text]
70. Mansat, V., Laurent, G., Levade, T., Bettaieb, A., and Jaffrezou, J. P. (1997) Cancer Res. 57, 5300-5304[Abstract]
71. Bettaieb, A., Plo, I., Mansat-De Mas, V., Quillet-Mary, A., Levade, T., Laurent, G., and Jaffrezou, J. P. (1999) Mol. Pharmacol. 55, 118-125[Abstract/Free Full Text]
72. Casaccia-Bonnefil, P., Carter, B. D., Dobrowsky, R. T., and Chao, M. V. (1996) Nature 383, 716-719[CrossRef][Medline] [Order article via Infotrieve]
73. Haimovitz-Friedman, A., Cordon-Cardo, C., Bayoumy, S., Garzotto, M., McLoughlin, M., Gallily, R., Edwards, C. K., 3rd, Schuchman, E. H., Fuks, Z., and Kolesnick, R. (1997) J. Exp. Med. 186, 1831-1841[Abstract/Free Full Text]
74. Hauck, C. R., Grassme, H., Bock, J., Jendrossek, V., Ferlinz, K., Meyer, T. F., and Gulbins, E. (2000) FEBS Lett. 478, 260-266[CrossRef][Medline] [Order article via Infotrieve]
75. Huwiler, A., Pfeilschifter, J., and van den Bosch, H. (1999) J. Biol. Chem. 274, 7190-7195[Abstract/Free Full Text]
76. Segui, B., Andrieu-Abadie, N., Adam-Klages, S., Meilhac, O., Kreder, D., Garcia, V., Bruno, A. P., Jaffrezou, J. P., Salvayre, R., Kronke, M., and Levade, T. (1999) J. Biol. Chem. 274, 37251-37258[Abstract/Free Full Text]
77. Tonnetti, L., Veri, M. C., Bonvini, E., and D'Adamio, L. (1999) J. Exp. Med. 189, 1581-1589[Abstract/Free Full Text]
78. Allouche, M., Charrad, R. S., Bettaieb, A., Greenland, C., Grignon, C., and Smadja-Joffe, F. (2000) Blood 96, 1187-1190[Abstract/Free Full Text]
79. Pahan, K., Khan, M., and Singh, I. (2000) J. Neurochem. 75, 576-582[CrossRef][Medline] [Order article via Infotrieve]
80. Separovic, D., He, J., and Oleinick, N. L. (1997) Cancer Res. 57, 1717-1721[Abstract]
81. Singh, I., Pahan, K., Khan, M., and Singh, A. K. (1998) J. Biol. Chem. 273, 20354-20362[Abstract/Free Full Text]
82. Kondo, T., Matsuda, T., Tashima, M., Umehara, H., Domae, N., Yokoyama, K., Uchiyama, T., and Okazaki, T. (2000) J. Biol. Chem. 275, 8872-8879[Abstract/Free Full Text]
83. Tepper, A. D., Cock, J. G., de Vries, E., Borst, J., and van Blitterswijk, W. J. (1997) J. Biol. Chem. 272, 24308-24312[Abstract/Free Full Text]
84. Lin, X., Hengartner, M. O., and Kolesnick, R. (1998) J. Biol. Chem. 273, 14374-14379[Abstract/Free Full Text]
85. Boucher, L. M., Wiegmann, K., Futterer, A., Pfeffer, K., Machleidt, T., Schutze, S., Mak, T. W., and Kronke, M. (1995) J. Exp. Med. 181, 2059-2068[Abstract]
86. Lisanti, M. P., Tang, Z., Scherer, P. E., and Sargiacomo, M. (1995) Methods Enzymol. 250, 655-668[Medline] [Order article via Infotrieve]
87. Belka, C., Marini, P., Lepple-Wienhues, A., Budach, W., Jekle, A., Los, M., Lang, F., Schulze-Osthoff, K., Gulbins, E., and Bamberg, M. (1999) Oncogene 18, 4983-4992[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.